Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Tenax Therapeutics Inc(TENX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TENX
09/25/2026: TENX (3-star) is currently NOT-A-BUY. Pass it for now.
Tenax Therapeutics is a clinical-stage biotechnology company focused on developing cardiovascular therapies, most notably its lead candidate Levosimendan. The company's primary investment story centers on the potential for its novel inodilator to address significant unmet medical needs in heart failure and pulmonary hypertension. While this focus offers high growth potential, the firm lacks current commercial revenue and faces substantial execution risks related to clinical trial outcomes and regulatory hurdles. Investors should note that the company is capital-intensive and requires ongoing financing. Consequently, Tenax may best suit risk-tolerant investors who monitor clinical trial progress and binary regulatory milestones as key developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential high growth if clinical trials succeed, but lacks a current revenue-generating commercial product. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find value during clinical trial milestone announcements or positive regulatory news cycles. |
| Value investor | Weak fit | The company is not currently profitable, making traditional valuation metrics like P/E ratios inapplicable. |
| Dividend investor | Weak fit | Tenax does not pay dividends and requires significant capital for development. |
| Low-risk investor | Weak fit | The high volatility and clinical binary risk profile are generally unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to sharp price swings based on clinical trial results and financing news. |
| Valuation risk | High | Valuation is speculative and heavily dependent on the projected future success of its clinical pipeline. |
| Competition risk (Cardiovascular) | Medium / high | The company competes with much larger, well-capitalized firms in the cardiovascular drug market. |
| Business quality | Medium | The company is in the process of validating its business model through clinical trial success. |
| Dividend income | Low / none | There is no income component to the investment. |
| Execution risk | High | Failure to meet clinical endpoints would severely impact the viability of the company. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 161.96% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.74M USD | Price to earnings Ratio - | 1Y Target Price 12.56 |
Price to earnings Ratio - | 1Y Target Price 12.56 | ||
Volume (30-day avg) 5.9M shares | Beta 0.82 | 52 Weeks Range 1.31 - 19.40 | Updated Date 09/27/2026 |
52 Weeks Range 1.31 - 19.40 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cardiovascular Therapeutics | Clinical development of Levosimendan for PH-HFpEF. | The company is currently not generating commercial sales and is funding development through investor capital. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 0.3 | Enterprise Value -46.31M | Price to Sales(TTM) 414.72 |
Enterprise Value -46.31M | Price to Sales(TTM) 414.72 | ||
Enterprise Value to Revenue 263.34 | Enterprise Value to EBITDA -0.14 | Shares Outstanding 37.42M | Shares Floating 30.78M |
Shares Outstanding 37.42M | Shares Floating 30.78M | ||
Percent Insiders 0.15 | Percent Institutions 110.81 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Tenax Therapeutics Inc
Exchange NASDAQ | Headquarters Chapel Hill, NC, United States | ||
IPO Launch date 1997-01-02 | CEO, President & Director Mr. Christopher T. Giordano | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.tenaxthera.com |
Full time employees 14 | Website https://www.tenaxthera.com | ||
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.